Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), a clinical-stage biopharmaceutical company, has engaged IBN to assist with its corporate communications strategy. The move is designed to generate greater awareness for the company and its wholly owned subsidiary, MindWave Innovations, which is developing institutional digital asset infrastructure. IBN will leverage its investor-focused distribution network, including more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire, and other outreach tools, to amplify Apimeds' corporate narrative.
The engagement matters because it signals Apimeds' intent to bridge two distinct investment theses: biopharmaceutical development and blockchain-based financial infrastructure. While Apimeds itself focuses on non-opioid, biologic-based therapies for pain management, MindWave Innovations is building enterprise blockchain infrastructure through its MindChain ecosystem. That ecosystem includes four verticals: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, measuring, verifying, and tokenizing ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.
For investors, the partnership with IBN could improve the visibility of APUS shares among a broader audience of institutional and retail investors. IBN's distribution capabilities are substantial, and by tapping into that network, Apimeds aims to ensure that its dual focus on biotech and digital assets is understood by the market. The company's newsroom, available at https://ibn.fm/APUS, will serve as a central hub for updates.
The full press release detailing the engagement can be viewed at https://ibn.fm/PdvmC. Apimeds Pharmaceuticals US, Inc. is focused on developing non-opioid, biologic-based therapies for pain management, and more information is available at www.ApimedsUS.com. MindWave Innovations Inc., a wholly owned subsidiary, is developing enterprise blockchain infrastructure and institutional technology platforms through its MindChain ecosystem.
The strategic communications push comes as institutional interest in digital assets continues to evolve, with a growing emphasis on insured custody, transparent reporting, and technology-driven portfolio management. MindWave's platform aims to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy. By engaging IBN, Apimeds is positioning itself to communicate these complex offerings more effectively to potential investors and partners.
MissionIR, the platform facilitating this engagement, is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit www.MissionIR.com. The terms of use and disclaimers applicable to all content provided by MIR are available at https://www.MissionIR.com/Disclaimer.
